KTTA Company Profile and Key Details

Pasithea Therapeutics Corp. generated EPS of -$5.08 over the past year. Five-year average earnings growth is -282.28%. Wall Street analysts project EPS growth of 48.53% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $3.00 to $3.00. The high target offers 466.04% upside. The low target suggests 466.04% downside. The mean target is $3.00. This offers 466.04% upside. Pasithea Therapeutics Corp. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 14, 2026, missed forecasts by 0.0%. The prior quarter beat by -73.33%. Over the last six quarters, Apple has recorded several small beats. These include 250.0% in May 16, 2022.

Short-term trend indicators are mixed aligned (SMA20 6.5%, SMA50 -9.97%, SMA200 1.65%). The stock’s 14-day RSI is 51.62 (neutral), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -77.9% below its high and over 198.11% above its low. Average 10-day trading volume of 217.76 thousand shares is below the 3-month average of 706.98 thousand, indicating normal recent market interest.

Pasithea Therapeutics Corp. has 33.41 million shares outstanding. The public float is 16.62 million shares, elevated short interest at 0.74% of float. This equals 242.87 thousand shares. The short ratio is 0.15 days. Institutional investors hold 71.13% of the float. Insiders own 1.11%. Coastlands Capital LP holds 3.84 million shares, Shahinian Eric has 1.79 million shares and Camac Partners, LLC has 1.79 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Pasithea Therapeutics Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $13.25. This means the shares are trading below this model’s fair value.

Pasithea Therapeutics Corp. (NASDAQ:KTTA) closed at $0.53 USD, losing -$0.01 (-1.85%) from the previous close of $0.54. The stock is currently mid-range between its 52-week high and low $0.28 and $2.06. With a market capitalization of about $17.71 million, Pasithea Therapeutics Corp. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.29). Key stats such as the average daily volume over the past year has been around 714.22 thousand shares, volume is running light vs its 52-week average. Headquartered in Miami Beach, FL, Pasithea Therapeutics Corp. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Tiago Reis Marques, the company employs approximately 5 people and listed since September 15, 2021. Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions.

Pasithea Therapeutics Corp. trades at a P/E ratio of -0.22, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.07 suggesting the stock is closer to book value. The P/FCF stands at -1.0, also above market averages.

Our AI price prediction model suggests that Pasithea Therapeutics Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.09%, with price expected at $0.61 by September 25, 2026, within a range of $0.59 to $0.62 3-Month Outlook: Projected fall of -18.87%, reaching $0.43 by December 10, 2026, with a range of $0.38 to $0.47. 1-Year Outlook: Projected gain of 11.32%, with price at $0.59 by September 10, 2027, within a range of $0.00 to $0.33.

Pasithea Therapeutics Corp. (NASDAQ:KTTA) shares are down -28.11% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Pasithea Therapeutics Corp. trading at a premium to the broader market with a P/E of -0.22. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $2.50, suggesting 371.7% upside. Our AI forecast model points to short-term strength (15.09% over two weeks), a medium-term fall (-18.87% over three months), and a longer-term gain (11.32% over one year), with expected trading ranges indicating moderate volatility.